Patients' understanding of the reasons for starting and discontinuing inhaled corticosteroids

British Journal of Clinical Pharmacology

Volumn 66, Issue 2, 2008, Pages 255-260

  Menckeberg, Tanja T ^a   Bouvy, Marcel L ^a,b   Bracke, Madelon ^a   Hugtenburg, Jacqueline G ^c   Lammers, Jan Willem ^d   Raaijmakers, Jan A M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adherence; Continuity of care; Discontinuing treatment; Inhaled corticosteroids; Pharmacist; Symptom experience

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPREHENSION; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NETHERLANDS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEASONAL VARIATION; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 47249152274     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03168.x     Document Type: Article

References (25)

1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2007. Available from: http://www.ginasthma.org (last accessed 10 February 2008).
2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2007. Available at http://www.goldcopd.org (last accessed 10 February 2008).
3. Eisner MD, Lieu TA, Chi F, Capra AM, Mendoza GR, Selby JV, Blanc PD. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001 17 : 233 40.
4. Shireman TI, Heaton PC, Gay WE, Cluxton RJ, Moomaw CJ. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002 36 : 557 64.
5. van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir Med 2003 97 : 578 85.
6. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004 98 : 752 9.
7. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med 1999 93 : 763 9.
8. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994 149 (2 Pt 2 S69 76.
9. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients' problems with new medication for chronic conditions. Qual Saf Health Care 2004 13 : 172 5.
10. World Health Organisation. Adherence to Long-Term Therapies. Evidence for Action. Geneva : WHO, 2003.
11. Buurma H, Bouvy ML, De Smet PAGM, Floor-Schreudering A, Leufkens HGM, Egberts ACG. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 2008 33 : 17 23.
12. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999 14 : 902 7.
13. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006 100 : 616 21.
14. Haughney J, Barnes G, Partridge M, Cleland J. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J 2004 13 : 28 35.
15. Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. Chest 2006 129 : 573 80.
16. Irwin RS, Richardson ND. Patient-focused care: using the right tools. Chest 2006 130 (1 Suppl. 73S 82S.
17. Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA 2007 297 : 831 41.
18. Haahtela T. The disease management approach to controlling asthma. Respir Med 2002 96 (Suppl. A S1 8.
19. McLean WM, MacKeigan LD. When does pharmaceutical care impact health outcomes? A comparison of community pharmacy-based studies of pharmaceutical care for patients with asthma. Ann Pharmacother 2005 39 : 625 31.
20. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, Seshadri R, Caffrey H, Roesner JF, Smith F, Newell AJ, Collins JC, McDonald CJ, Tierney WM. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 2002 288 : 1594 602.
21. Amruso NA, O'Neal ML. Pharmacist and physician collaboration in the patient's home. Ann Pharmacother 2004 38 : 1048 52.
22. Keely JL. Pharmacist scope of practice. Ann Intern Med 2002 136 : 79 85.
23. Pinnock H, Bawden R, Proctor S, Wolfe S, Scullion J, Price D, Sheikh A. Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ 2003 326 : 477 9.
24. Pinnock H, Madden V, Snellgrove C, Sheikh A. Telephone or surgery asthma reviews? Preferences of participants in a primary care randomised controlled trial. Prim Care Respir J 2005 14 : 42 6.
25. Roberts NJ, Partridge MR. Telephone consultations in secondary care. Respir Med 2007 101 : 1665 9.